Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. by Federico, Massimo et al.
| 1482 | haematologica/the hematology journal | 2007; 92(11)
Prognostic relevance of serum β2 microglobulin in patients
with follicular lymphoma treated with anthracycline-containing
regimens. A GISL study
Massimo Federico, Cesare Guglielmi, Stefano Luminari, Caterina Mammi, Luigi Marcheselli,
Umberto Gianelli, Antonino Maiorana, Francesco Merli, Monica Bellei, Samantha Pozzi,
Caterina Stelitano, Antonio Lazzaro, Paolo G. Gobbi, Luca Baldini, Stefania Bergantini,
Vittorio Fregoni, Maura Brugiatelli
From Dipartimento di Oncologia ed
Ematologia, Università di Modena e
Reggio Emilia, Modena (MF, SL,
CM, LM, MoB, SP); Dipartimento di
Biotecnologie Cellulari ed Ematologia,
Università "La Sapienza", II Facoltà di
Medicina e Chirurgia, Roma (CG, SB);
Cattedra di Anatomia Patologica,
Dipartimento di Medicina, Chirurgia e
Odontoiatria, Università degli Studi di
Milano, A. O. S. Paolo e Fondazione
Ospedale Maggiore Policlinico,
Mangiagalli e Regina Elena di Milano
(UG); Dipartimento Integrato Servizi
Diagnostici e di Laboratorio, Università
di Modena e Reggio Emilia, Modena
(AM); Unità Operativa di Ematologia,
A.O. S. Maria Nuova, Reggio Emilia
(FM); Divisione di Ematologia, Azienda
Ospedaliera “Bianchi-Melacrino-
Morelli”, Reggio Calabria (CS);
Dipartimento di Oncologia ed
Ematologia, Ospedale Guglielmo da
Saliceto, Piacenza (AL); Medicina
Interna, Oncologia Medica, Università
di Pavia, IRCCS Policlinico S. Matteo,
Pavia (PGG); Unità Malattie
Linfoproliferative, Dipartimento di
Ematologia, Centro G. Marcora,
Ospedale Maggiore, IRCCS, Milano
(LB); U. O. Oncologia Medica I, IRCCS,
Fondazione Salvatore Maugeri, Pavia
(VF); Divisione di Ematologia, Azienda
Ospedaliera Papardo, Messina (MaB).
Funding; this work was partially
supported by a grant from the
Fondazione Cassa di Risparmio di
Modena and the Associazione Angela
Serra per la Ricerca sul Cancro,
Modena, Italy.
Manuscript received March 12, 2007.
Manuscript accepted September 5,
2007.
Correspondence: Massimo Federico,
MD, Dipartimento di Oncologia ed
Ematologia, Centro Oncologico
Modenese, Università di Modena e
Reggio Emilia, Policlinico, Via del Pozzo
71, 41100 Modena, Italy.
E-mail: federico@unimore.it
Background and Objectives
Although serum β2 microglobulin (β2M) is an easy parameter to measure, and over-
expressed in a large number of lymphoproliferative diseases, its prognostic value has
been largely underestimated. The present study examined the influence of β2M lev-
els on overall survival (OS) of patients with follicular lymphoma (FL).
Design and Methods
The prognostic role of β2M was evaluated in 236 patients with FL identified from the
databases of the Gruppo Italiano per lo Studio dei Linfomi (GISL) and treated with
anthracycline-based regimens from 1993 to 2003.
Results
Elevated serum β2M levels were found in 82 patients (35%). According to multivari-
ate logistic regression analysis, elevated β2M levels were associated with elevated
lactate dehydrogenase (LDH) (p=0.021), age (p=0.029), and number of involved
nodal areas (p<0.001). The percentage of elevated β2M levels increased progressive-
ly with increasing FLIPI scores (17%, 38%, and 63% in the low-, intermediate-, and
high-risk groups, respectively). Five-year OS was 61% (95% CI, 47-73%) and 89% (95%
CI, 82-93%) for patients with elevated vs normal β2M levels respectively (p<0.001).
Cox regression analysis showed that β2M level had an independent and stable prog-
nostic value (HR=3.0; 95%CI, 1.6-5.7). In a multivariate analysis the impact of β2M
level on survival was independent of FLIPI score, with a HR of 2.94 (95% CI, 1.54-
5.62).
Interpretation and Conclusions
Our results demonstrate that in patients treated in the pre-rituximab era, β2M level
was an independent prognostic marker in addition to FLIPI score. We thus suggest
that β2M be routinely assessed and tested in future prognostic studies of FL patients
treated with combination chemotherapy and anti-CD20 agents. 
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ABSTRACT
Follicular lymphoma (FL) is one of the most frequentand well-characterized subtypes of malignant lym-phoma in Western countries and accounts for ~10-
15% of all malignant lymphomas in adults.1 The disease
is usually characterized by an indolent clinical course,
impressive response to initial therapy, frequent relapses,
and response to salvage therapy of shorter duration.
Despite continuous efforts to develop effective therapies
for FL, population-based studies have shown only modest
improvements in long-term survival over the last 30
years.2 As a result, the appropriate initial therapy for FL
patients remains a matter of debate. Several treatment
options are available, ranging from no initial treatment
(i.e., watchful waiting), to high-dose therapy, requiring
hematopoietic stem cell support.3 With such a range of
options, it is generally agreed that initial treatment should
be chosen according to the risk of disease progression in
individual patients.
To date, several attempts have been made to better
define the prognosis of patients with FL. A predictive
model of survival in FL patients was first proposed by the
Italian Lymphoma Intergroup (ILI).4 The ILI prognostic
index is based on six factors: age, gender, B-symptoms,
number of extranodal (EN) sites of disease, erythrocyte
sedimentation rate (ESR), and serum lactate dehydroge-
nase (LDH) levels. More recently, the Follicular
Lymphoma Prognostic Factor Project developed the
Follicular Lymphoma International Prognostic Index
(FLIPI) based on age, Ann Arbor stage, hemoglobin (Hb)
level, number of nodal areas involved and LDH levels.5
The ILI and FLIPI indices define three risk categories asso-
ciated with different survival rates. However, although
the indices have demonstrated clinical relevance, they suf-
fer from the limitation of their retrospective nature and
share potential biases.6 For instance, though significantly
associated with outcome at univariate analysis, it was
decided not to include serum β2 microglobulin (β2M) in
the test sample of the FLIPI because of the very high pro-
portion of patients with missing data. 
β2M is a low molecular weight, single polypeptide chain
that is considered the light-chain molecule of the major
histocompatibility complex class I antigens. β2M is found
on the membrane surface of almost all nucleated cells. It is
particularly plentiful on the surface of white blood cells,
and white blood cell membrane turnover is the principal
source of serum β2M.7,8 Increased levels of β2M have been
found to be of prognostic relevance in a wide variety of
malignancies, including multiple myeloma,9 chronic lym-
phocytic leukemia,10 Hodgkin’s lymphoma,11 and aggres-
sive and indolent lymphomas in general.12,13
Here we present the results of a study on the prognos-
tic value of serum β2M levels in FL patients who were
treated by the Gruppo Italiano per lo Studio dei Linfomi
(GISL) in prospective clinical trials for 10 years prior to the
advent of anti-CD20 therapy. We analyzed the effects of
β2M levels on survival and evaluated the additional prog-
nostic value of β2M levels in FLIPI-identified risk groups.
Design and Methods
The archive of patients enrolled in one of the prospec-
tive clinical trials of the GISL group was our source for
patient selection. All clinical trials selected for this study
were approved by local ethical committees and by the
review board of the GISL. All patients signed an informed
consent form prior to starting treatment in accordance
with the ethical standards of the responsible committee
on human experimentation and with the declaration of
Helsinki. The possibility of performing future unplanned
analyses was explicitly indicated in the study protocol
and in the informed consent forms. The current study
was considered ethically acceptable by the review board
of the GISL. To be considered for the study, patients had
to have a diagnosis of FL (any grade) made between 1993
and 2003, be 18-75 years of age, have Ann Arbor stage I-
IV disease, have information on serum β2M levels at time
of diagnosis and have been treated with anthracycline-
containing combination chemotherapy. Patients with
stage I-II disease were only enrolled if they had bulky dis-
ease or were three or more involved areas. A study data
set was defined that included demographics, clinical and
laboratory features at diagnosis, treatment details, and
follow-up information. BCL-2 gene status was not rou-
tinely assessed; therefore, we did not include it in the data
set. All baseline data, including β2M levels, were collect-
ed by people who were blind to the patients’ treatment
and outcome. 
The extent of disease was coded according to the Ann
Arbor staging system and assessed by clinical examina-
tion, chest and abdomen computed tomography scan,
and bone marrow trephine biopsy. Response to treatment
was determined 1 month after the end of induction ther-
apy with the examinations necessary to verify the
absence of abnormal findings at diagnosis. All evaluations
of stage and response to treatment were based on data
recorded by GISL investigators. Response criteria for non-
Hodgkin’s lymphoma proposed by the International
Workshop were applied.14 Unconfirmed complete
response was combined with complete response (CR) for
the purpose of the present analysis.
Statistical analysis
Fisher’s exact test was used to evaluate differences
between categorized distributed variables, whereas inde-
pendent factors related to β2M levels were assessed by
logistic regression analysis. Survival was calculated from
the date of diagnosis using the Kaplan-Meier method.
The log-rank test was used to compare subgroups in the
univariate analysis of survival. Multivariate analysis of
factors related to survival was performed using the Cox’s
proportional hazards regression method considering vari-
ables that were statistically significant according to the
univariate analysis. The proportional hazards assumption
was checked by the Grambsch-Therneau method. p val-
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ues <0.05 were considered statistically significant. The
coefficient stability of the Cox proportional hazards
regression, obtained by adjusting β2M levels by variables
with p<0.10 in the univariate analysis, was checked by a
bootstrap method.15 All analyses were performed with
Stata Statistical Software Release 8.0 (StataCorp, College
Station, TX, USA).
Results
Based on the study inclusion criteria, 236 (81%) out of
291 FL patients were selected from the GISL archives for
the present analysis. The median age of the patients was
57 years (range 25-77 years) with 36% of patients over 60
years old. The main clinical characteristics of the study
population are shown in Table 1. Eighty-two patients
(35%) had serum β2M levels above the upper normal
limit (UNL). Finally, according to the FLIPI, 45%, 32%,
and 23% of cases were classified at low, intermediate, or
high risk, respectively. Clinico-laboratory characteristics
and outcome of the 236 patients with available β2M val-
ues did not differ from those of the remaining 55 cases
(data not shown).
All patients received immediate treatment with an
anthracycline-containing regimen. One hundred and
eighty-seven patients were treated with a CHOP-like reg-
imen, and 49 patients were treated with a
PromaceCytaBOM-like regimen. A median of six cycles
of chemotherapy (range, 2-8 cycles) was given. The
chemotherapy program was completed in 229 (97%) of
the patients, and it was interrupted due to complications
in seven (3%) patients.  Forty-seven (20%) patients
received local irradiation after chemotherapy because of
initial bulky disease or the presence of residual masses;
involved field radiation treatment was administered to
13/21 patients with stage I disease and in 16/48 cases with
stage II.
Radiotherapy was always administered as involved
field treatment. With induction therapy, 171 patients
(72%) achieved a CR, 47 (20%) a partial response, and 18
(8%) patients were classified as non-responders. Fifty
patients relapsed after a median interval from diagnosis of
23 months. Salvage treatment for patients with progres-
sive or relapsed disease consisted of chemotherapy with
or without radiotherapy (n=53), high dose chemotherapy
followed by stem cell transplantation (n=9), radiotherapy
M. Federico et al. 
| 1484 | haematologica/the hematology journal | 2007; 92(11)
Table 1. Patients’ baseline clinical features.
Features Total No. No. %
Gender Male 236 120 51
Age > 60 years 236 85 36
Ann Arbor stage III-IV 236 167 71
No. of extranodal sites >1 236 52 22
No. of nodal areas > 4 236 74 31
Performance status >1 236 5 2
B-symptoms present 236 33 14
LDH level > UNL 228 42 18
ESR ≥ 30 mm/h 223 52 23
Hemoglobin level < 12 g/dL 232 38 16
Albumin level < 3.5 g/dL 223 28 13
Serum β2M level > UNL 236 82 35
FLIPI risk
Low 102 45
Intermediate 225 71 32
High 52 23
LDH: lactate dehydrogenase; ESR: erythrocyte sedimentation rate; β2M: β2
microglobulin; FLIPI: follicular Lymphoma International; Prognostic Index;
UNL: upper normal limit. 
Table 2. Univariate and multivariate logistic regression analyses
for β-2 microglobulin levels and clinical and laboratory baseline
features.
Features β-2M > UNL Univariate Multivariate
% p value p value
Gender
Male 38 0.413
Female 32
Age
≤60 years 31 0.154
> 60 years 41
Age (continuous form)
Median 58 0.014 0.029
(range) (29-75)
Ann Arbor stage
I-II 20 0.003
III-IV 41
No. of extranodal sites
0-1 30 0.005
>1 52
No. of nodal areas
0-4 26 <0.001 <0.001
> 4 53
Performance Status
0-1 35 >0.5
2 40
B-symptoms
absent 32 0.047
present 52
LDH level
UNL 30 0.004 0.021
> UNL 55
ESR
< 30 mm/h 33 0.250
≥30 mm/h 42
Hemoglobin level
≥12 g/dL 30 0.001
< 12 g/dL 61
Albumin level
≥3.5 g/dL 32 0.011
< 3.5 g/dL 57
β2M: β2 microglobulin; LDH: lactate dehydrogenase; UNL: upper normal limit;
ESR: erythrocyte sedimentation rate.
alone (n=2), palliative or no treatment (n=10), or
unknown treatment (n=11). Rituximab alone or in combi-
nation with other therapies was used in 22 patients who
received salvage therapy since 1999. Forty-six (20%)
patients died at a median interval of 27 months (range 1-
88 months) after diagnosis. Thirty-three patients died of
disease progression and 13 patients died while off-thera-
py in CR (3 cases) or in partial response not requiring fur-
ther therapy (10 cases). After a median follow-up of 46
months (range, 3-140 months) for all cases and 51 months
(range, 5-140) for surviving patients, the 5-year survival
rate was 80% (95% confidence interval (CI), 73-85%).
The mortality rate was 4.5 % per year.
β2M levels at diagnosis
The frequency of elevated β2M levels, according to the
main clinical and laboratory parameters, is reported in
Table 2. According to univariate analysis with Fisher’s
exact test, elevated β2M levels were associated with Ann
Arbor stages III-IV (p=0.003), >1 extranodal sites of dis-
ease (p=0.005), >4 involved nodal areas (p<0.001), the
presence of B-symptoms (p=0.047), LDH level >UNL
(p=0.004), Hb <12 g/dL (p=0.001), and serum albumin
level <3.5 g/dL (p=0.011). Elevated β2M levels were also
associated with age when the variable was managed as a
continuous variable (p=0.014, Mann-Whitney test). In a
multivariate logistic regression analysis, β2M levels were
significantly associated with LDH >UNL (p=0.021), num-
ber of involved nodal areas (p<0.001) and age (p=0.029).
Survival analysis
According to univariate analysis, >1 extranodal sites of
disease, LDH >UNL, presence of B-symptoms, Hb levels
<12 g/dL, 1hr ESR ≥30 mm/hr, albumin levels <3.5 g/dL,
and β2M levels >UNL had a negative impact on survival
(Table 3). Performance status was not included in the uni-
variate analysis because of the low number of patients
with a poor performance status. In addition to the above-
mentioned parameters, FLIPI was also a strong predictor of
outcome with a 5-year survival rate of 90%, 78%, and
59% for patients at low, intermediate, and high risk,
respectively (p<0.001).
Patients with β2M >UNL had a 5-year survival of 61%
(95% CI, 47-73%) vs. 89% (95% CI, 82-93%) for patients
with β2M ≤UNL (p<0.001; Figure 1). The hazard ratio
(HR) for β2M in univariate analysis was 4.1 (95% CI, 2.2-
7.4). The multivariate Cox regression model also con-
firmed the prognostic value of β2M (Table 4a). In particu-
lar, the discriminating power of β2M was only slightly
decreased by the inclusion of potentially confounding fac-
tors (HR=3.0, 95% CI, 1.6-5.7, p<0.001), confirming its
role as an independent prognostic factor. The prognostic
role of β2M levels was also confirmed in an analysis limit-
ed to patients with advanced stage disease (data not shown). 
Relationship between β2M levels and FLIPI
The proportion of patients with β2M >UNL increased
progressively with increasing FLIPI scores, being 17%,
38%, and 63% in the low-, intermediate-, and high-risk
groups, respectively (Spearman correlation=0.386, test for
trend p<0.001). The impact of β2M on survival was meas-
ured in each FLIPI risk group. In terms of 5-year survival,
the differences were statistically significant in the low
(92% vs. 82%, p=0.035) and intermediate (90% vs. 56%,
p=0.001) risk groups, but not in the smaller high risk group,
although also in this group a trend toward a better outcome
for patients with normal β2M values was observed (70%
vs. 53%, p=0.264; Figure 2). When both β2M and FLIPI
were included in a multivariate analysis of survival, the
independent prognostic value of β2M was confirmed, with
a HR of 2.94 (95% CI, 1.54-5.62; Table 4b).
Discussion
Despite serum β2M level being an easy parameter to
measure, so far its prognostic value has been largely
β2 microglobulin in follicular lymphoma
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Table 3. Univariate analysis of survival according to baseline clin-
ical and laboratory features.
Features 5-year survival rate Univariate analysis
% 95% CI p value
Gender
Male 75 64-83 0.145
Female 83 74-90
Age
60 years 81 72-88 0.082
>60 years 76 64-85
Ann Arbor stage
I-II 87 74-94 0.151
III-IV 76 68-83
No. of extranodal sites
0-1 82 75-88 0.024
>1 68 50-81
No. of nodal areas
0-4 81 73-87 0.124
>4 76 63-86
B-symptoms
absent 84 77-89 <0.001
present 54 33-70
LDH level
≤UNL 88 82-93 <0.001
>UNL 42 25-58
ESR
<30 mm/h 87 79-92 0.002
≥30 mm/h 61 44-74
Hemoglobin level
≥12 g/dL 83 76-88 0.002
<12 g/dL 59 39-75
Albumin level
≥3.5 g/dL 83 76-88 0.002
<3.5 g/dL 54 30-73
Serum β2M level ≤
≤UNL 89 82-93 <0.001
>UNL 61 47-73
CI: confidence interval; LDH: lactate dehydrogenase; ESR: erythrocyte
sedimentation rate; β2M: β2 microglobulin; UNL: upper normal limit.  
underestimated. In fact, although β2M was identified
more than 30 years ago and was found to be a promising
prognostic factor in most lymphoproliferative disorders,
few attempts have been made to assess its relevance in a
prognostic index. A prognostic index based on serum
β2M levels was proposed for patients with diffuse large B-
cell lymphoma in the late 1980s, and a simple score based
on β2M and LDH levels was able to identify patients with
different risks of death.16
In a more recent study, baseline serum β2M levels were
found to be independent prognostic factors, along with
molecular response. Based on this observation, Lopez-
Guillermo et al. proposed that FL patients could be strati-
fied into prognostic groups according to baseline β2M lev-
els and molecular response to induction therapy.17
The prognostic value of β2M serum levels was
assessed in two studies dealing with the risk of histolog-
ical transformation, with apparently conflicting results.
In the study by Bastion et al., β2M was the only inde-
pendent prognostic factor.18 In the more recent study by
Gine et al. FLIPI and histological subtype, but not β2M,
were found to have independent prognostic roles.19
However, it is notable that Bastion et al. did not analyze
FLIPI as a risk factor.
Unfortunately β2M, although significantly associated
with survival at univariate analysis, was not included in
the test sample of FLIPI and in the final scoring system
because of the very high proportion of patients with miss-
ing data (available in 17% of cases).5 Insufficient measure-
ments of β2M also precluded the inclusion of β2M levels
in other prognostic models, such as ILI and IPI.4,20
We tested the prognostic value of β2M in a large series
of FL patients who were homogeneously treated with
upfront anthracycline-containing regimens in the context
of controlled clinical trials performed by the GISL. In
order to be included in these clinical trials patients were
required to have an ambulatory Performance Status and
in particular to have normal renal function, thus limiting
the chance that medical conditions other than lymphoma
could lead to altered β2M levels. The almost complete
compliance with induction therapy (completed in 97% of
cases), along with the homogeneity of treatment (all
patients were treated with anthracycline-containing regi-
mens), the appropriate observation time (which exceeded
4 years for patients at risk of death), and the limited num-
ber of patients lost to follow-up (n=4) allow us to main-
tain that this series of patients was appropriate for an
accurate prognostic evaluation of β2M levels. That is, for
patients with FL elevated β2M levels have a strong
adverse prognostic value, being associated with a poorer
outcome in terms of long-term survival. It is also relevant
that β2M retained its prognostic value in a multivariate
analysis performed including all the prognostic parame-
ters utilized in the FLIPI, IPI, and ILI indices. Although
FLIPI was useful for classifying patients into different risk
groups in our study sample, we found that β2M level had
an additional, independent value in discriminating prog-
M. Federico et al. 
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Table 4. Multivariate Cox regression analysis of overall sur-
vival for β2 microglobulin levels and parameters with p-values
<0.10 from univariate analysis (a) and for β2 microglobulin
levels and FLIPI (b).
Features HR 95% CI p value Boot Boot
95% CI p value
Panel (a)
Serum β2M level ≤
≤UNL 1.0
>UNL 3.0 1.6-5.7 0.001 1.4-6.4 0.005
Age
≤60 years 1.0
> 60 years 2.0 1.1-3.7 0.027 1.0-4.2 0.059
No. of extranodal sites
0-1 1.0
>1 1.2 0.6-2.4 0.537 0.6-2.7 0.610
B-symptoms
absent 1.0
present 1.8 0.9-3.6 0.074 0.8-4.3 0.155
LDH level
≤UNL 1.0
>UNL 3.0 1.5-6.1 0.002 1.3-6.9 0.009
ESR
<30 mm/h 1.0
≥30 mm/h 1.3 0.7-2.7 0.438 0.5-3.2 0.543
Hemoglobin level
≥12 g/dL 1.0
<12 g/dL 1.2 0.6-2.5 0.641 0.5-3.1 0.728
Albumin level
≥3.5 g/dL 1.0
<3.5 g/dL 1.2 0.6-2.6 0.573 0.5-2.9 0.621
Panel (b)
Serum β2M level
≤UNL 1.00
>UNL 2.94 1.54-5.62 0.001 1.45-5.97 0.003
FLIPI
0-1 1.00
2 1.64 0.76-3.57 0.207 0.72-3.76 0.238
≥3 3.10 1.41-6.73 0.005 1.31-7.26 0.010
HR: hazard ratio; CI: confidence interval; β2M: β2 microglobulin; LDH: lactate
dehydrogenase; ESR: erythrocyte sedimentation rate; FLIPI: Follicular
Lymphoma International Prognostic Index; UNL: upper normal limit.
Figure 1. Overall survival according to baseline β2Mlevels.
Continuous line, β2M≤UNL; broken line; β2M>UNL; β2M: β2
microglobulin; UNL: upper normal limit.
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nosis. Our data suggest that the prognostic effect of β2M
is also retained in the three FLIPI groups, although it
seems to be more evident in the low and the intermedi-
ate-risk groups. However in the high risk group the lack
of a statistically significant difference could have depend-
ed on the smaller number of cases falling in this category
in our study sample. The association between β2M levels
and survival suggests that soluble β2M reflects an impor-
tant biological process that is somehow correlated with
tumor mass. In fact, we found that β2M levels were sig-
nificantly associated with elevated baseline LDH levels
and with the number of nodal areas involved. Similarly, in
our study, high β2M levels were correlated with anemia,
which could be considered an effect of bone marrow
involvement by lymphoma. The strong independent
effect of β2M on survival suggests that β2M may not be a
simple surrogate of tumor mass but could reflect some
still unknown biological characteristics of the tumor or of
the microenvironment, with an additive effect on the risk
of death. With multivariate logistic analysis, we found an
association between elevated β2M and age when the lat-
ter was analyzed as a continuous variable (Table 2); this
association could be explained by an effect of the differ-
ent biology of the elderly patient on β2M (i.e. reduced cre-
atinine clearance). Although correlated, both age and β2M
level retained independent roles in predicting overall sur-
vival, thus suggesting that in the population of patients
with FL analyzed in the present study age had only a lim-
ited role, if any, on the increase of β2M.
At present, it is not known whether the prognostic
value of β2M in B-cell lymphomas can be altered by treat-
ment. This is particularly relevant for FL patients, for
whom the  addition of anti-CD20 monoclonal antibody
to chemotherapy has been shown to improve survival
compared to chemotherapy alone.21,22 As in the FLIPI, IPI,
and ILI studies, none of the patients in our series received
rituximab as part of their initial therapy. For this reason,
we are cautious about generalizing our results to patients
treated with anti-CD20 monoclonal antibody therapies.
However, based on the recent study by Buske et al. who
demonstrated that in patients treated with CHOP plus rit-
uximab, FLIPI maintained its discriminating power,23 we
can expect that the prognostic role of β2M will also be
confirmed. Our study demonstrates that information on
β2M serum levels may contribute, significantly and inde-
pendently from FLIPI, to the prognostic definition of FL
patients treated upfront with anthracycline-containing
chemotherapy. The role of serum β2M levels in the prog-
nosis of FL must be confirmed in future studies investigat-
ing FL patients treated with combination chemotherapy
plus anti-CD20 agents.
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Figure 2. Survival in FLIPI risk groups according to baseline β2
microglobulin levels. Top: score 0-1; middle: score 2; bottom:
score 3-5 stratified according to β2M level. Continuous line: β2M
≤UNL; broken line: β2M >UNL. FLIPI: follicular Lymphoma
International Prognostic Index; β2M: β2 microglobulin; UNL: upper
normal limit. 
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